About Human Papillomavirus Type 16 (HPV16) L2 Recombinant Protein

Human Papillomavirus Type 16 (HPV16) is the most prevalent high-risk papillomavirus associated with cervical cancer, anogenital cancers, and HPV-positive head and neck cancers. The L2 protein is the minor capsid protein of HPV16 and plays essential roles in viral assembly, genome encapsidation, endosomal escape, intracellular trafficking, and delivery of the viral genome into the host cell nucleus. Although less abundant than the major capsid protein L1, L2 contains highly conserved epitopes shared among diverse HPV types, making it an attractive target for the development of broad-spectrum HPV vaccines and cross-neutralizing antibodies.

eEnzyme's Human HPV16 L2 Recombinant Protein is produced for research use and is suitable for studies of HPV biology, antibody generation, ELISA development, Western blotting, epitope mapping, protein-protein interactions, and vaccine research. This recombinant protein provides a valuable reagent for investigating HPV infection mechanisms, host immune responses, and the development of next-generation prophylactic vaccines and antiviral therapeutics.

Applications

Applications

Biological Significance of HPV16 L2

HPV16 L2 is a multifunctional capsid protein that facilitates viral genome packaging, intracellular trafficking, and nuclear delivery during infection. Because its N-terminal region contains highly conserved neutralizing epitopes across multiple HPV genotypes, L2 has emerged as a promising antigen for the development of pan-HPV vaccines capable of providing broader protection than current L1-based vaccines. The Human HPV16 L2 Recombinant Protein provides a valuable research tool for studies of HPV pathogenesis, vaccine development, and immune response characterization.